Trial begins to deliver coronavirus vaccine via an inhaler

Henrietta Strickland
September 15, 2020

In an interview with "Face the Nation", Bourla said it's not yet known whether Americans will be able to receive a coronavirus vaccine before 2021, as issuance of a license depends on federal regulators.

While AZ and Oxford have been highlighted as race leaders, so too are Pfizer and BioNTech, who said they now want to boost their phase 2/3 trial for one of their five mRNA vaccines, BNT162b2, from around 30,000 to 44,000.

In less than six weeks since the study began, 31,000 volunteers representing 125 nationalities have participated in the clinical trials.

"We go to younger people".

"It's going to take four to five years until everyone gets the vaccine on this planet", Poonawalla said, reports FT.

Novavax Inc last month separately said SK Bioscience, a unit of SK Chemicals, would manufacture a component of the USA drug developer's experimental coronavirus vaccine in a bid to boost its supply.

"I wanted to liberate our scientists from any bureaucracy", he said.

Bourla said he gave Pfizer's team an "open checkbook" so they only have to worry about "scientific challenges". Plus, he added, he wanted to keep Pfizer out of politics, a tall task for a pharma company on any day, but especially during this pandemic.

This was the first indication that the US trial will remain on hold until the US Food and Drug Administration and a safety panel investigate the case.

Coronavirus Vaccine latest: The Coronavirus vaccine could be available in the USA before the end of this year, claimed American pharmaceutical company Pfizer CEO Albert Bourla.

"This is likely to be a very staged market entry", he said on "Face the Nation".

"If we are not shooting at a moving target here, the chances are this vaccine is far more effective".

The results of the first and second test phases showed that the vaccine was safe, effective and triggered the right response.

A unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and USA -listed Sinovac Biotech SVA.O are developing the three vaccines under the state's emergency use programme.

Dr Chiu said: "We have evidence that delivering influenza vaccines via a nasal spray can protect people against flu as well as help to reduce the transmission of the disease".

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER